Naomi C Sacks1, Philip L Cyr2, Arthur C Louie3, Yanmei Liu4, Michael T Chiarella3, Abhishek Sharma4, Karen C Chung5. 1. Precision Health Economics, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts. Electronic address: Naomi.Sacks@precisionhealtheconomics.com. 2. Precision Health Economics, Boston, Massachusetts; University of North Carolina, Charlotte, North Carolina. 3. Jazz Pharmaceuticals Inc, Ewing, New Jersey. 4. Precision Health Economics, Boston, Massachusetts. 5. Jazz Pharmaceuticals Inc, Palo Alto, California.
Abstract
PURPOSE: Acute myeloid leukemia (AML) disproportionately affects older adults; the prognosis in this subpopulation is generally poor, with variable use of inpatient chemotherapy. This study characterizes treatment patterns, hospitalizations, and outcomes among older patients with AML. METHODS: Using the Centers for Medicare & Medicaid Services' 2010-2012 100% Limited Data Set (LDS), data from all hospital claims from fee-for-service Medicare beneficiaries between 60 and 75 years of age with newly diagnosed AML and ≥1 hospitalization were analyzed. FINDINGS: Among 3700 identified patients with AML, 1979 (53.5%) received chemotherapy. Hospitalization rates were highest initially and then declined over time, irrespective of chemotherapy use. The mean length of initial hospital stay was longer in patients receiving chemotherapy. Intensive care unit admissions occurred in 33% of initial hospitalizations. Factors associated with receiving chemotherapy included younger age, fewer comorbidities, and the absence of prior hematologic disorders. Chemotherapy was associated with significantly increased survival compared with no chemotherapy (P < 0.0001). IMPLICATIONS: AML in older patients is associated with frequent hospitalizations and intensive care unit admissions. New treatment options with more favorable risk-to-benefit profiles are needed in this population.
PURPOSE:Acute myeloid leukemia (AML) disproportionately affects older adults; the prognosis in this subpopulation is generally poor, with variable use of inpatient chemotherapy. This study characterizes treatment patterns, hospitalizations, and outcomes among older patients with AML. METHODS: Using the Centers for Medicare & Medicaid Services' 2010-2012 100% Limited Data Set (LDS), data from all hospital claims from fee-for-service Medicare beneficiaries between 60 and 75 years of age with newly diagnosed AML and ≥1 hospitalization were analyzed. FINDINGS: Among 3700 identified patients with AML, 1979 (53.5%) received chemotherapy. Hospitalization rates were highest initially and then declined over time, irrespective of chemotherapy use. The mean length of initial hospital stay was longer in patients receiving chemotherapy. Intensive care unit admissions occurred in 33% of initial hospitalizations. Factors associated with receiving chemotherapy included younger age, fewer comorbidities, and the absence of prior hematologic disorders. Chemotherapy was associated with significantly increased survival compared with no chemotherapy (P < 0.0001). IMPLICATIONS: AML in older patients is associated with frequent hospitalizations and intensive care unit admissions. New treatment options with more favorable risk-to-benefit profiles are needed in this population.
Authors: Antonio Solana-Altabella; Juan Eduardo Megías-Vericat; Octavio Ballesta-López; Blanca Boluda; Isabel Cano; Evelyn Acuña-Cruz; Rebeca Rodríguez-Veiga; Laura Torres-Miñana; Claudia Sargas; Miguel Á Sanz; Carmela Borrell-García; Eduardo López-Briz; José Luis Poveda-Andrés; Javier De la Rubia; Pau Montesinos; David Martínez-Cuadrón Journal: Cancers (Basel) Date: 2022-04-11 Impact factor: 6.639
Authors: Lih-Wen Mau; Christa Meyer; Linda J Burns; Wael Saber; Patricia Steinert; David J Vanness; Jaime M Preussler; Alicia Silver; Susan Leppke; Elizabeth A Murphy; Ellen Denzen Journal: JNCI Cancer Spectr Date: 2019-08-28